Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study

Autor: Johannes Jakobsen, Henning Andersen, Danish Cidp, Ingelise Christiansen, Niels Kjær Olsen, Lars Høj Markvardsen, Søren H. Sindrup

Publikováno v: Markvardsen, L H, Sindrup, S H, Christiansen, I, Olsen, N K, Jakobsen, J, Andersen, H & Danish CIDP and MMN Study Group 2017, ' Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy : randomized controlled trial study ', European Journal of Neurology, vol. 24, no. 2, pp. 412-418 . https://doi.org/10.1111/ene.13218
Markvardsen, L H, Sindrup, S H, Christiansen, I, Olsen, N K, Jakobsen, J & Andersen, H 2017, ' Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. ', European Journal of Neurology, vol. 24, no. 2, pp. 412-418 . https://doi.org/10.1111/ene.13218
Markvardsen, L H, Sindrup, S H, Christiansen, I, Olsen, N K, Jakobsen, J, Andersen, H & On behalf of The Danish CIDP and MMN Study Group 2017, ' Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy : randomized controlled trial study ', European Journal of Neurology, vol. 24, no. 2, pp. 412-418 . https://doi.org/10.1111/ene.13218

BACKGROUND AND PURPOSE: Subcutaneous immunoglobulin (SCIG) is effective as maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). We investigated whether multiple subcutaneous infusions are as effective as conventional the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b1c9fca944122c2bb13a8e50f0295e7
https://doi.org/10.1111/ene.13218

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.